Business
Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar
All proposals approvedCompany not implementing a reverse split at this timeSwiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM
About this update from Jaguar Health, Inc.
[{"type":"text","content":"All proposals approvedCompany not implementing a reverse split at this timeSwiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Eastern regarding appearance of new coronavirus strain underscoring urgency to seek European conditional approval for crofelemer for ‘long-hauler' syndrome gastrointestinal distress as strategy pursued in potential merger of Napo EU with the European Post Pandemic Recovery Equity special purpose acquisition company (SPAC)SAN FRANCISCO, CA / ACCESSWIRE / December 22, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) (''Jaguar'' or the ''Company'') today announced the voting results of Jaguar's December 9, 2020 Special Meeting of Stockholders (the \"Special Meeting\"), which, as previously announced, was adjourned until December 22, 2020.Two proposals were submitted to and approved by the stockholders of the Company at the Special Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Special Meeting filed with the SEC on November 6, 2020. Stockholders may obtain a free copy of the proxy statement and other documents filed by Jaguar with the SEC at http://www.sec.gov. The proxy statement is also available on the Company's corporate website.\"Although we do not intend to effect a reverse split of the Company's issued and outstanding voting common stock at this time, we are grateful to our shareholders for voting to approve the related proposal,\" Lisa Conte, Jaguar's president, and CEO said. \"Jaguar's Board and management are optimistic about the future, and seeking the discretion to implement actions, if necessary to maintain Jaguar's Nasdaq listing, is an important responsibility of the Board.\"As announced last week, Jaguar completed a road show with Swiss Growth Forum, a sponsor of the European special purpose acquisition company, \"Post Pandemic Recovery Equity\" (\"the SPAC\"). Napo EU, a subsidiary the Company plans to establish in Europe focusing on development of crofelemer for diarrhea related to ‘long-hauler' post COVID-19 recovery patient syndrome, is the target of a potential merger with the SPAC, which is targeting investment between 20 million and 50 million euros. Napo EU will have an exclusive license to crofelemer for Europe (excluding Russia), the Company's novel proprietary drug, and obligations to d...